The Expand Study-Pharmacist Administered Long Acting Cabotegravir + Rilpivirine to Expand Access for People With HIV

Launched by METROHEALTH MEDICAL CENTER · Oct 8, 2024

Keywords

ClinConnect Summary

The EXPAND study is a clinical trial designed to explore a new way for people living with HIV to receive their medication more conveniently. Instead of always going to a clinic for their injections, patients may be able to get their long-acting HIV medication, cabotegravir and rilpivirine, from a licensed pharmacist at local pharmacies. This study will look at how well this method works compared to the standard practice of getting injections from a nurse in a clinic. Researchers want to understand if patients find it acceptable and if it is a practical solution for delivering their medication.

To participate in this study, you need to be at least 18 years old and already diagnosed with HIV. You should currently be receiving the medication cabotegravir and rilpivirine every 4 or 8 weeks and have had at least two doses of it before. Your last test should show that you have very low levels of the virus (less than 50 copies per milliliter). You'll also need to be able to follow the study rules and speak English. If you join the study, you can expect to receive your injections at a pharmacy nearby, and researchers will check how well this new method works for you compared to the usual clinic visits.

Gender

ALL

Eligibility criteria

• Patient Participant Inclusion Criteria:
• • 18 years of age and older
• • diagnosed with HIV by approved HIV screen and confirmation test
• • currently on CAB+RPV LA every 4 or 8 weeks
• • has received at least two doses of CAB+PRV LA
• • last HIV-1 RNA \<50 copies/ml
• • no known or suspected resistance to either cabotegravir or rilpivirine
• • no plans to change medication in the next 48 weeks
• • no plans to move out of state
• • has plans to avoid pregnancy if of reproductive potential
• Patient Participant Exclusion Criteria:
• • individuals who are unable or unwilling to adhere to the study protocol
• • unable to speak/comprehend English
• • insurance coverage for medication through medical benefit
• Staff Participant Inclusion/Exclusion Criteria:
• • -all available staff involved in the CAB+RPV LA workflow will be approached for inclusion